PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation

Autologous stem cell transplantation (ASCT) remains the standard of care for patients with relapsed/refractory (RR) classical Hodgkin lymphoma (cHL) who respond to salvage chemotherapy. However, relapse after ASCT remains a frequent cause of treatment failure, with poor subsequent prognosis. Because...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Armand, Philippe, Chen, Yi-Bin, Redd, Robert A., Joyce, Robin M., Bsat, Jad, Jeter, Erin, Merryman, Reid W., Coleman, Kimberly C., Dahi, Parastoo B., Nieto, Yago, LaCasce, Ann S., Fisher, David C., Ng, Samuel Y., Odejide, Oreofe O., Freedman, Arnold S., Kim, Austin I., Crombie, Jennifer L., Jacobson, Caron A., Jacobsen, Eric D., Wong, Jeffrey L., Patel, Sanjay S., Ritz, Jerome, Rodig, Scott J., Shipp, Margaret A., Herrera, Alex F.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2019
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6609955/
https://ncbi.nlm.nih.gov/pubmed/30952672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000215
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge